Valuation: Pelthos Therapeutics Inc.

Market Cap 9.92Cr 8.59Cr 8.01Cr 7.37Cr 14Cr 943.21Cr 14Cr 94Cr 37Cr 471.94Cr 37Cr 36Cr 1.56TCr P/E 2026 *
-2.44x
P/E 2027 * -15.7x
Enterprise Value 9.92Cr 8.59Cr 8.01Cr 7.37Cr 14Cr 943.21Cr 14Cr 94Cr 37Cr 471.94Cr 37Cr 36Cr 1.56TCr EV / Sales 2026 *
1.55x
EV / Sales 2027 * 0.82x
Free-Float
46.22%
Yield 2026 *
-
Yield 2027 * -
1 day+6.89%
1 week+10.88%
Current month-0.42%
1 month+10.75%
3 months+12.14%
6 months+22.38%
Current year-7.94%
1 week 25.92
Extreme 25.92
29.09
1 month 23.51
Extreme 23.51
29.09
Current year 18.19
Extreme 18.19
30.99
1 year 16.5
Extreme 16.5
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Sell

Director

-558 0.0161%
02/07/26 Sell

Director

-786 0.0226%
02/07/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
+6.89%+10.88%+35.90% - 9.92Cr
+4.86%-3.32%+52.73%+160.26% 1,04300Cr
+1.04%-2.99%+50.87%+52.38% 62TCr
+0.98%-6.49%+24.00%+66.66% 44TCr
+0.40%+3.74%+47.47%+38.42% 36TCr
+0.77%-1.06%+35.80%+39.61% 29TCr
-0.50%-5.55%+8.68%+10.36% 25TCr
+4.57%+5.21%+35.91%+67.64% 22TCr
+1.24%-9.82%+3.07%-45.32% 20TCr
-2.58%-0.73%+17.16%+67.46% 16TCr
Average +1.43%-2.34%+31.16%+50.83% 35.89TCr
Weighted average by Cap. +0.84%-3.79%+38.49%+76.23%

Financials

2026 *2027 *
Net sales 6.39Cr 5.54Cr 5.16Cr 4.75Cr 8.96Cr 607.76Cr 9.06Cr 61Cr 24Cr 304.09Cr 24Cr 23Cr 1.01TCr 12Cr 10Cr 9.78Cr 9Cr 17Cr 1.15TCr 17Cr 114.97Cr 45Cr 576.53Cr 46Cr 45Cr 1.91TCr
Net income -4.14Cr -3.58Cr -3.34Cr -3.07Cr -5.8Cr -393.53Cr -5.87Cr -39Cr -15Cr -196.9Cr -16Cr -15Cr -652.13Cr -67.38L -58.36L -54.4L -50.04L -94.46L -64Cr -95.52L -6.39Cr -2.51Cr -32Cr -2.53Cr -2.48Cr -106.18Cr
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
05/26/05 $28.54 +6.89% 59,723
04/26/04 $26.70 -0.52% 1,32,726
03/26/03 $26.84 -6.35% 3,74,480
31/26/31 $28.66 +9.18% 3,24,265
30/26/30 $26.25 +1.98% 1,66,063
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
28.54USD
Average target price
57.71USD
Spread / Average Target
+102.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock